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Prostaglandin G/H synthase (PGG/HS) is the rate- 
limiting enzyme  in  the  conversion  of  arachidonic  acid 
to prostaglandins and thromboxanes. We screened a 
human lung fibroblast cDNA library with an ovine 
PGG/HS  cDNA  and isolated  a 2.3-kilobase clone (HCO- 
T9). Sequence analysis of this clone  showed  that (a) it 
contained  the  entire  translated  region  of  PGG/HS  and 
(b)  it displayed an in-frame splicing of the last 111 
base  pairs  encoded  by  exon 9, which  resulted in the 
elimination of  the N-glycosylation site at residue 409. 
Polymerase  chain  reaction  amplification with specific 
oligonucleotides of reverse-transcribed mRNA from 
diverse human tissues and  cultured cells yielded 400- 
and 300-base pair fragments that corresponded, re- 
spectively, to the intact and spliced transcripts. The 
expression  of  these two transcripts  in  cultured human 
lung  fibroblasts was differentially regulated  by  serum, 
transforming  growth  factor B1, interleukin  18, tumor 
necrosis  factor (x, and phorbol12-myristate 13-acetate, 
as each  of  these  conditions  stimulated preferentially 
the expression  of  the  unspliced  transcripts.  The elimi- 
nation of one  of  the  four N-glycosylation sites by  the 
alternative splicing of exon 9 and  the differential reg- 
ulation of this process by relevant cytokines and 
growth factors may represent a mechanism for the 
regulation  of PGG/HS enzymatic activity under  phys- 
iological or pathological  conditions. 
Prostaglandins (PG)’ are important mediators involved in 
diverse biologic processes such as cell proliferation, inflam- 
matory  and immune responses, smooth muscle contraction, 
maintenance of fluid and electrolyte balance, platelet aggre- 
gation,  and the production of extracellular matrix  proteins 
(1-3). The metabolism of free arachidonic acid to PG  and 
thromboxanes is dependent on the availability of the enzyme 
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The abbreviations used are: PG,  prostaglandin(s);  PGG/HS, pros- 
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MEM, Eagle’s minimal essential medium; FCS, fetal calf serum; 
PMA, phorbol 12-myristate 13-acetate; PCR, polymerase chain re- 
action. 
PG G/H synthase (PGG/HS) (EC 1.14.99.1), a membrane- 
bound homodimer of two  70-kDa polypeptides. PGG/HS  has 
a bisdioxygenase (cyclo-oxygenase) activity mediating the 
bisoxygenation of arachidonic acid to the hydroperoxide 
PGGZ, and a hydroperoxidase activity mediating the reduction 
of  PGGz to  the endoperoxide PGHz, which is  the precursor of 
PG  and thromboxanes (4,5).  PGG/HS is a hemoprotein with 
a protoporphyrin IX prosthetic group which is required for 
both cyclo-oxygenase and hydroperoxidase activities. The  en- 
zyme contains four oligosaccharides bound to asparagine res- 
idues (6). At  least one of these residues appears to play a 
crucial role in  the activity of the enzyme. 
The primary structure of PGG/HS from ovine vesicular 
glands (7-9) and murine 3T3 cells (10) has been deduced from 
full-length cDNA sequences. Similarly, the primary structure 
of the human enzyme has been deduced from sequences of a 
genomic clone (1 1). Northern hybridizations employing ovine 
or murine cDNAs have identified either 2.7-kb transcripts 
that correspond to  the size of the cDNA (12,13)  or  transcripts 
of 2.7 and 5.5 kb (14-16) in a variety of cells and tissues from 
different species, including humans. In addition, hybridiza- 
tions under low stringency conditions showed the presence of 
4.0-kb transcripts  in  murine  and ovine tissues, suggesting the 
existence of a related gene  (17, 18). More recently, the avian 
equivalent of this gene has been cloned (19). 
PG have been shown to down-regulate the production of 
extracellular matrix  proteins  in fibroblasts by diverse mech- 
anisms (3). PG production is  stimulated by various cytokines, 
such as  interleukin 18 (IL-l@), tumor necrosis factor a (TNF- 
a), transforming growth factor B1 (TGF-P1), epidermal growth 
factor, and platelet-derived growth factor (20-24). Conse- 
quently, PG may modulate the effects that these cytokines 
have on extracellular matrix protein production (22). The 
availability of a cDNA for the human  PGG/HS would  allow 
a better  understanding of the complex regulatory processes 
involved in PG production in various tissues under diverse 
conditions. 
Here, we report the cloning of a cDNA for the human PGG/ 
HS and present evidence of an alternative splicing of the 
corresponding mRNA that eliminates 111 bp encoded by exon 
9 of the gene. The alternative splicing would result in the 
elimination of one of the four functionally required N-glyco- 
sylation sites in the enzyme. Furthermore, we demonstrate 
the differential regulation of PGG/HS mRNA splicing by 
serum, TGF-P’, IL-1P, TNF-a, and phorbol esters. These 
observations suggest that  the alternative splicing we identified 
may play an important role in the regulation of the enzymatic 
activity of PGG/HS under normal or pathologic conditions. 
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MATERIALS AND  METHODS 
Cell Culture-Primary fibroblast cultures were established from 
human lung, dermis, and synovium and were cultured as described 
(25). Confluent fibroblasts were incubated for 24 h  in Eagle's minimal 
essential medium (MEM)  supplemented with 1, 5,  or 10%  FCS, 1% 
(v/v) vitamins, and 2 mM L-glutamine. After this period, the cells 
were incubated for different intervals  in media containing either no 
serum or serum at  the same concentrations as those received during 
the previous 24  h. The cultures were incubated  under  control condi- 
tions or with one of the following additives: 0.1 p~ phorbol 
12-myristate 13-acetate (PMA), 200 units/ml TNF-a (Boehringer 
Mannheim), 50 units/ml  IL-10 (Boehringer Mannheim) or various 
concentrations of TGF& (10-500 PM) (Collaborative Research Inc., 
Bedford, MA). 
Northern Hybridizations-Poly(A+) mRNA was prepared  on 
oligo(dT)lo-cellulose columns using the  Fast  Track mRNA Isolation 
Kit (Invitrogen; San Diego,  CA). Total RNA from human cartilage 
was obtained as described (26). Total RNA from confluent lung, 
dermal, and synovial fibroblasts was prepared by the guanidinium 
isothiocyanate/CsC12 discontinuous gradient method as described 
(27). Total RNA or poly(A+) mRNA was electrophoresed on  formal- 
dehyde-agarose gels, transferred to nylon-supported nitrocellulose 
(Schleicher & Schuell), UV cross-linked, and hybridized with either 
a gel-purified 1.6-kb cDNA for ovine PGG/HS (7), the corresponding 
human HCO-T9 cDNA (see below), or a murine glyceraldehyde-3- 
phosphate dehydrogenase cDNA (28). Probes were labeled with [a- 
'"PIdCTP by nick translation (29), and  the filters were hybridized for 
24 h at  42 "C in 4 X SSC, 50% formamide, 0.1% sodium dodecyl 
sulfate,  2 X Denhardt's solution, and 200 pg/ml salmon  sperm DNA. 
Autoradiographs were developed and  then scanned in a  laser  densi- 
tometer  (UltroScan  XL,  Pharmacia LKB Biotechnology Inc.). 
Isolation and Characterization of the cDNA-Single-stranded 
cDNA was prepared by reverse transcription of 5 pg  of human  lung 
fibroblast poly(A+) mRNA with Moloney leukemia virus reverse 
transcriptase (GIBCO-BRL) and oligo(dT)lo primers (30), and  the 
second strand was synthesized using RNase  H and DNA polymerase 
I (Boehringer Mannheim). EcoRI linkers  (Promega Biotec, Madison, 
WI) were attached to  the double-stranded cDNA, and  it was ligated 
to  an EcoRI-predigested X vector (X-ZAP II; Stratagene, La Jolla, 
CA), and packaged in uitro using a commercial packaging extract 
(Giga Pack I1 Plus;  Stratagene,  La  Jolla, CA). A bacteriophage cDNA 
library was obtained  containing approximately 4.5 X IO5 colonies and 
was screened by plaque hybridization with the gel-purified 1.6-kb 
ovine PGG/HS cDNA previously radiolabeled with [ ( U - ~ ~ P I ~ C T P  by 
nick translation to a specific activity of 1.5 X 10* cmp/pg DNA. 
Hybridizations were carried out for 48 h at 42 "C  in  a buffer containing 
6 X SSC, 5 X Denhardt's  solution, 1% sodium dodecyl sulfate, and 
100 pg/ml salmon sperm DNA. A positive clone was identified that 
was plaque-purified, and  the Bluescript phagemide containing the 
cDNA was excised from the X vector with the helper virus R408. 
Progressive bidirectional deletions of the double-stranded cDNA were 
prepared with exonuclease 111 (Erase-a-Base  System, Promega Bio- 
tec)  and sequenced by the dideoxy chain termination method (31) 
using modified T7 polymerase (Sequenase, U. S. Biochemical Corp.). 
Polymerase Chain Reaction (PCR) Amplification of PGG/HS Tran- 
scripts-Total RNA (5-10 pg) or poly(A+) mRNA (2 pg) from various 
human tissues and cultured cells was employed to synthesize single- 
stranded cDNA with Moloney leukemia virus reverse transcriptase 
and oligo(dT)lo primers. Amplification of the cDNA was performed 
by 40 cycles of PCR (32) in 50 pl of Taq DNA polymerase mixture 
(Perkin-Elmer  Cetus Instruments) with 25 PM of two primers  flank- 
ing a region from nucleotides 1011 to 1415. The reaction cycles were 
94 "C for 30 s, 52  "C for 30 s, and 72  "C for 1 min. The 5"primer (5'- 
GGAGACCATCAAGATTGT) is complementary to the antisense 
strand,  and  the 3"primer (5"GTTCTCCAAACCGTACTT) is com- 
plementary to the sense strand. The PCR-amplified cDNAs were 
directly cloned into  the pCR-1000 vector (Invitrogen, San Diego,  CA) 
and sequenced by the dideoxy chain termination method. 
In other experiments, 4 pg of total RNA from lung fibroblasts 
incubated under various conditions were reverse-transcribed using 
random hexamers and amplified by PCR in the presence of 25  pCi of 
[a-"'PIdCTP for 20 cycles. The reactions were chloroform-extracted 
and precipitated, resuspended in H20,  and divided into two aliquots 
and analyzed by electrophoresis in 3% agarose and 5% acrylamide, 
respectively. In  other reactions, 3 or 8 pg  of total RNA were reverse- 
transcribed and amplified by PCR  in  the presence of 50 pCi of [a- 
'"PIdCTP in a reaction volume of 200 pl, and 38-pl aliquots were 
taken at  cycles 15, 18, 21, 24, 27. Each aliquot was divided and 
analyzed by electrophoresis in agarose and acrylamide gels as de- 
scribed above. Acrylamide gels were fixed in 7% acetic acid, dried, 
and subjected to autoradiography. The segments of the gels corre- 
sponding to  the bands  detected by autoradiography were excised, and 
the radioactivity was determined by scintillation counting. The 
counts/min  obtained were divided by the cytidine content of both 
strands of the cDNA corresponding to  the  intact  and spliced tran- 
scripts flanked by the oligonucleotide primers used for amplifications; 
that is cpm in 400 bp/210 and cpm in 300 bp/144. The resulting 
values were used for further calculations. 
RESULTS 
Cloning and Sequencing of a Full-length  Human PGGIHS 
cDNA and Evidence of Alternative Splicing-Northern hy- 
bridizations of poly(A+) mRNA from normal human lung 
fibroblasts with the 1.6-kb ovine PGG/HS cDNA showed 
hybridization to 2.7-kb and 5.5-kb transcripts  (Fig. 1, lane 1). 
A  bacteriophage cDNA library  was  prepared  from this mRNA 
and a positive clone containing a 2.3-kb cDNA, referred to as 
HCO-T9, was obtained. Northern hybridization analysis of 
normal  human  lung  fibroblast poly(A+) mRNA with the HCO- 
T9 clone showed  transcripts  of  2.7  and  5.5  kb (Fig. 1, lane 2). 
A  partial restriction map and the sequencing strategy for the 
HCO-T9 clone are shown in Fig.  2. 
The nucleotide  sequence  of the HCO-T9 clone was deter- 
mined and compared  with the sequence of the human  genomic 
clone for PGG/HS (ll), which encodes for the 2.7-kb tran- 
script (Fig. 3). This analysis showed that  the HCO-T9 clone 
has the following features. (a )  It contains the entire coding 
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FIG. 1. Northern  hybridizations  of  normal human lung fi- 
broblast mRNA with ovine and  human PGG/HS cDNAs. Two 
pg of poly(A+) mRNA isolated from normal  human lung fibroblasts 
was electrophoresed and blotted onto nitrocellulose as described 
under  "Materials and Methods." Lane 1, mRNA hybridized with the 
1.6-kb ovine cDNA for PGG/HS labeled by nick translation with a 
[ c ~ - ~ ' P ] ~ C T P  (specific activity, 5.9 X 10' cpm/pg). Lane 2, mRNA 
hybridized with the 2.3-kb human HCO-T9 clone labeled by nick 
translation with [ c ~ - ~ ~ P ] ~ C T P  (specific activity, 1.29 X 10' cpmlpg). 
Sizes in kb were determined by comparison with transcripts for 
fibronectin and glyceraldehyde-3-phosphate dehydrogenase. 
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the human PGG/HS cDNA. The 2.3-kb HCO-T9 clone was digested 
FIG. 2. Partial restriction map  and sequencing strategy of 
with exonuclease 111 to obtain bidirectional deletions. The arrows 
indicate the direction and lengths of the sequencing reactions. 
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FIG. 3. Nucleotide and predicted amino acid sequences of 
the HCO-T9 cDNA. Nucleotides and amino acids are numbered 
from the ATG initiation codon. The nucleotides corresponding to 
exon 9 that are absent from clone HCO-T9 are underlined with a 
solid line. Binding sites for forward and reverse oligonucleotide 
primers for PCR analysis are underlined with a discontinuous line. 
The 5'- and 3'-ends of exon 9 are marked with arrowheads. The four 
N-glycosylation sites (residues 67, 103,  143, and 409) are boxed. The 
serine  that is  acetylated by aspirin (residue 529) is marked with a 
dot. 
has a complete homology with the the genomic sequence, 
except for the nucleotides at  positions 36, 338,393, and 1133. 
( c )  It shows the absence of 111 bp (from nucleotides 1186 to 
1296) corresponding to  the  last 111 bp of exon 9, coding for 
37 amino acids (amino acids 396-432). The 3'-acceptor site 
of exon 10 is  conserved, thereby maintaining the PGG/HS 
single open reading frame. The presence of the consensus 
sequence C/AAGGTG/A of 5"splice donor sites (33) from 
nucleotides 1183 to 1188 of exon 9 strongly suggested an 
alternative splicing of the PGG/HS  transcripts. 
Expression of Intact and Spliced PGGIHS Transcripts  in 
Various Tksues and Cultured Cells-To investigate whether 
transcripts corresponding to the intact and alternatively 
spliced forms of the  PGG/HS gene  were expressed in different 
human cells, PCR amplification of cDNA prepared from fetal 
and adult cartilage and from dermal, lung, and synovial fibro- 
blast mRNA was performed. The ovine 1.6-kb (intact)  and 
the human HCO-T9 (spliced) cDNAs  were also amplified as 
controls. The 18-mer primers used were designed to bind 
regions of perfect homology between the human and ovine 
cDNAs. PCR amplification of the reverse transcribed mRNA 
from the five different human sources resulted in two frag- 
ments of approximately 400 and 300 bp in every  case  (Fig.  4). 
PCR amplification of mRNAs extracted from synovial tissue 
produced fragments of the same sizes (data  not shown). PCR 
amplification of the ovine  1.6-kb  cDNA  yielded a single frag- 
ment of the expected 400 bp, whereas amplification of the 
HCO-T9 yielded a single fragment of 300 bp (Fig. 4). The 
300-bp and 400-bp fragments amplified from the human 
mRNA and  the 400- and 300-bp fragments amplified from 
the 1.6-kb ovine and  the HCO-T9 cDNAs,  respectively,  were 
cloned in the pCR-1000 vector and sequenced. Analysis of the 
sequences showed that ( a )  the 400-bp fragments from both 
species were derived from transcripts corresponding to  an 
intact exon 9  and (b) the human 300-bp fragment lacked the 
last 111 bp encoded by exon 9.  We conclude that there was 
indeed an alternative splicing of the human PGG/HS mRNA 
at  a position corresponding to nucleotide 1185 of exon 9 of 
the gene. 
Regulation of the  Expression of Intact  and Spliced PGGIHS 
Transcripts by Growth Factors and Cytokines-The possibility 
that there may  be differences in  the enzymatic activity of the 
proteins  translated from the  intact  and alternatively spliced 
transcripts led us to investigate the relative expression of 
these  transcripts in normal human lung fibroblasts, under in 
vitro conditions known to up-regulate the expression of the 
gene (12,14,17,34-39). Fibroblasts incubated with increasing 
concentrations of TGF-PI showed a dose-dependent increase 
(up  to 17-fold at  500 PM TGF-PI) in  the steady-state levels of 
the 2.7-kb PGG/HS  transcript (Fig. 5A). I t  was also noted 
that  the 5.5-kb transcript described above  was coordinately 
expressed with the 2.7-kb PGG/HS  transcript.  To determine 
the effects of the higher concentrations of TGF-B1 on the 
relative proportions of intact and spliced PGG/HS tran- 
scripts, total RNA from control and  TGF-&-treated cells  was 
reverse-transcribed and amplified by PCR. Aliquots taken at  
different cycles were electrophoresed in agarose and acryl- 
-400 bp - 300 bp 
1 2 3 4 5 6 7  
FIG. 4. Analysis of  mRNA from various human tissues and 
cells by PCR amplification with PGG/HS-specific  oligonucle- 
otide primers. Ten pg of total RNA (cartilage, dermal, and lung 
fibroblasts), or 2 pg of poly(A+) mRNA (synovial fibroblasts), was 
by PCR as described under "Materials and Methods." The PCR 
reverse-transcribed, and equal aliquots were amplified for 40 cycles 
products were analyzed in a 1.5% agarose gel stained with ethidium 
bromide. Lane 1, fetal  tibial cartilage; lane 2, adult  tibial cartilage; 
lane 3, dermal fibroblasts; lane 4, lung fibroblasts; lane 5, synovial 
fibroblasts; lane 6, ovine 1.6-kb cDNA, lane 7, HCO-T9 clone. The 
DNA standard ladders (left) are X DNA-BstEII and Phix174 RF 
DNA-HwIII. 
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FIG. 5. Northern hybridizations and PCR analysis of mRNA 
from normal  human lung fibroblasts stimulated with TGF-8,. 
A, confluent normal human  lung  fibroblasts were incubated  in  MEM 
(1% FCS) with various concentrations of TGF-6, for 24 h. Total 
RNA  was  isolated as described under  “Materials  and  Methods”  and 
10-pg aliquots were analyzed by Northern hybridizations with the 
HCO-T9 clone (specific activity, 1 x 10” cpm/pg) and a murine 
glyceraldehyde-3-phosphate  dehydrogenase  cDNA  (specific activity, 
1 X 10” cpmlpg). Lane 1, control; lanes 2-6, TGF-Dl, 10,50,100,250, 
and 500 p ~ ,  respectively. B, 8 pg of total RNA  from control  and 500 
PM TGF-&-treated cells was reverse-transcribed and amplified by 
PCR. Equal aliquots  taken at different cycles were electrophoresed 
in 5% acrylamide and processed as described under  “Materials  and 
Methods.” An autoradiograph of a 15-min exposure of the gel is 
shown. C, the radioactivity  from gel slices corresponding to the 
autoradiographic  bands was corrected for the  dCTP  content of the 
templates, as described under “Materials and Methods,” and their 
logarithms were plotted  against  the  number of cycles. The r values 
were  calculated  from cycles 15-21.0, 400-bp control ( r  = 0.9984); W, 
300-bp control ( r  = 0.9990); 0, 400-bp TGF& ( r  = 0.9965); 0, 300- 
hp  TGF-6, ( r  = 0.9533). I), 4 pg of total  RNA were reverse-transcribed 
and PCR-amplified  for 20 cycles, and  the  samples were processed as 
described under  “Materials  and Methods.” An autoradiograph of a 
15-min exposure of the gel is shown. Lane 1, control; lanes 2-6, TGF- 
PI, 10, 50, 100, 250, and 500 pM, respectively. 
amide as described under “Materials and Methods.” The 
autoradiographs of the acrylamide gel  showed a progressive 
amplification of the  intact (400 bp) and spliced (300 bp) PGG/ 
HS  transcripts, with higher levels of both  transcripts  in TGF- 
PI-treated cells at  all cycles of amplification examined (Fig. 
5B).  The relative extent of amplification of the  intact and 
spliced transcripts showed a linear increase from  cycles  15 to 
21 (Fig. 5C). It was, therefore, possible to obtain an accurate 
estimate of the relative ratios of the 400-bp/300-bp PCR- 
amplified products a t  cycle 18, the midpoint of the linear 
phase of the reaction. This ratio increased from  1.67 in control 
cells to 2.58 in  TGF-&-treated cells. A  similar analysis of cells 
treated with increasing concentrations of TGF-0, showed a 
dose-dependent increase in the levels of the  intact  and spliced 
transcripts (Fig. 50) ,  with a more pronounced increase in the 
levels of the  intact  transcripts relative to those of the spliced 
transcripts (Table  I). 
TNF-a  and  IL-lP caused a 1.6- and 2.3-fold increase in the 
steady-state levels of the 2.7-kb PGG/HS transcript, respec- 
tively, and a coordinated increase on the 5.5 kb band described 
above (Figs. 6A and 7A). The kinetics of PCR amplification 
of the reverse-transcribed mRNA showed a progressive incre- 
ment of the amplified products of the intact and spliced 
transcripts as the number of cycles increased, with higher 
levels of both  in TNF-CY and IL-I/?-treated cells (Figs. 6B and 
7B).  The relative extent of amplification of the  intact  and  the 
spliced transcripts showed linear increases from  cycles 15  to 
21 (Figs. 6C and 7C). The ratios of the 4OO-bp/3OO-bp PCR- 
amplified products a t  cycle 18 increased from 2.19 in control 
cells to 3.18 in TNF-a-treated cells and from 2.32 to 3.75 in 
IL-lp-treated cells (Table I). 
Treatment of fibroblasts with serum or PMA showed a 
time-dependent increase in the steady-state levels of the 2.7- 
kb PGG/HS  transcript  that reached 18- and 10-fold higher 
levels over control cells, respectively, (Fig. 8A). In addition, 
there was a coordinate increase in the expression of the 5.5- 
kb transcript  and of a minor transcript of  4.4  kb. PCR analysis 
TABLE I 
Relative expression of intact and spliced PGGIHS transcripts  in 
normal human  lung fibroblasts under various treatments 
Total RNA from normal human lung fibroblasts cultured under 
control conditions or under various treatments was reverse-tran- 
scribed and amplified by PCR  in  the presence of [n-’*P]dCTP, and 
the  products were resolved in 5% acrylamide gels as described under 
“Materials  and Methods.” The radioactivity of the gel slices corre- 
sponding to the  autoradiographic  bands was divided by the cytidine 
content of the  templates,  and  the  ratios f the amplified  cDNAs were 
calculated  with the following equation. Ratio = (cpm in 400 bp/210)/ 
(cpm in 300 bp/144). 
Experiment Condition 400-bp 300-bp Ratio 400/300 
1“ Control 87.0 52.0  1.67 
TGF-PI, 500 PM 211.1 81.6  2.58 
2“ Control 114.5 48.0  2.38 
TGF-PI, 10 PM 150.7 59.2 2.54 
TGF-61, 50 PM 248.6 89.2 2.78 
TGF-61, 100 pM 274.8 89.0 3.08 
TGF-61, 250 pM 434.0 131.4 3.30 
TGF-&,500 pM 834.9 266.3 3.13 
3” Control 18.2 8.3 2.19 
TNF-a, 200 units/ml 83.8 26.3  3.18 
4” Control 13.0 5.6  2.32 
IL-16, 50  units/ml 81.1 21.6 3.75 
5” Control 29.2 24.8 1.17 
10% FCS,  2  h 41.5 27.5 1.50 
10% FCS,  4  h 96.3 50.3 1.91 
10% FCS,  6  h 145.7 70.2  2.07 
PMA, 0.1 p M  129.1 58.8 2.19 
Amplified for 18 cycles. 
* Amplified for 20 cycles. 





1 2  
B 
1 -400 bp 
-300 bp 




Cycle 1 5  18  21  24  27 
FIG. 6. Northern hybridizations and PCR analysis  of mRNA 
from normal  human lung fibroblasts stimulated with  TNF-a. 
A, confluent normal human lung fibroblasts were incubated  in MEM 
(5%  FCS) with or without 200 units/ml TNF-a for 24  h. Total RNA 
was isolated as described under  “Materials and Methods”, and 5-pg 
aliquots were analyzed by Northern hybridizations with the HCO-T9 
clone (specific activity, 4.5 X 10’ cpm/pg) and a  murine glyceralde- 
hyde-3-phosphate dehydrogenase cDNA (specific activity, 2.6 X lo8 
cpm/pg). Lane I ,  control; lane 2, TNF-a. B, three pg of total RNA 
were reverse-transcribed and PCR-amplified. Equal aliquot taken a t  
a different cycle was electrophoresed on a 5% acrylamide gel and 
processed as described under  “Materials and Methods.” An autora- 
diograph of a 30-min exposure of the gel is shown. C, the radioactivity 
of gel slices corresponding to  the autoradiographic bands was cor- 
rected for the  dCTP  content of the templates as described under 
“Materials and Methods”, and  their logarithms were plotted  against 
the number of cycles. The r values were calculated from cycles 15- 
21. M, 400-bp control ( r  = 0.9940); m- - 4, 300-bp control ( r  
= 0.9930); W, 400-bp TNF-a ( r  = 0.9930); O - - U ,  300-bp 
TNF-a ( r  = 9996). 
at 20 cycles showed a parallel increase in the intact and 
spliced transcripts (Fig. 8B). Estimation of the 400-bp/300- 
bp ratios in serum-deprived cells showed an increase from 
1.17 to 2.07 and 2.1 following 6 h of serum stimulation and 4 
h of PMA stimulation, respectively (Table I). 
DISCUSSION 
We have been studying the role of PG as regulators of 
various human fibroblast functions and  their participation  in 
the modulation of the effects of several cytokines on collagen 
production by these cells (2,22). Cytokines such as IL-1P and 
TNF-a cause inhibition of collagen production, whereas TGF- 
PI is a potent  stimulant. All three cytokines also stimulate 
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FIG. 7. Northern hybridizations and PCR analysis  of mRNA 
from normal human lung fibroblasts stimulated with IL-la. 
A, confluent  normal  human  lung  fibroblasts were incubated  in MEM 
(5% FCS) with and without 50 units/ml  IL-16  for 24  h. Total RNA 
was isolated as described under  “Materials and Methods”, and 5-pg 
aliquots were analyzed by Northern hybridizations with the HCO-T9 
clone (specific activity, 4.8 X 10’ cpmlpg) and  the murine glyceral- 
dehyde-3-phosphate dehydrogenase cDNA (specific activity, 2.6 X 10’ 
cpmlpg). Lane I ,  control; lane 2, IL-16. B, three pg of total RNA were 
reverse-transcribed and PCR-amplified. Equal  aliquots taken at  dif- 
ferent cycles were electrophoresed on a 5% acrylamide gel and proc- 
essed as described under “Materials and Methods.” An autoradi- 
ograph of a 30-min exposure of the gel is shown. C, the radioactivity 
of gel slices corresponding to  the autoradiographic  bands was cor- 
rected for the dCTP content of the templates as described under 
“Materials and Methods,” and  their logarithms were plotted  against 
the number of cycles. The r values were calculated from cycles 15 to 
21. U, 400-bp control ( r  = 0.9963); C - 4, 300-bp control ( r  
( r  = 9909). 
= 0.9891); o”-o, 400-bp IL-10 ( r  = 0.9887); 0- - -0,300-bp IL-10 
production of PG, which are known inhibitors of collagen 
production. These  interactions suggest that  PG play a  central 
role in  the modulation of extracellular matrix  protein produc- 
tion, as well as in  other biological processes. To explore the 
mechanisms responsible for the regulation of PG production 
in human cells under diverse conditions, we obtained  a cDNA 
for the human PGG/HS, the rate-limiting enzyme in the 
metabolism of arachidonic acid to PG. The screening of a 
normal human  lung fibroblast cDNA library with an ovine 
cDNA for PGG/HS resulted in the isolation of a human 
PGG/HS cDNA. Northern hybridizations of lung fibroblast 
mRNA with this cDNA  showed strong hybridization to 2.7- 
kb  PGG/HS  transcripts  and to additional transcripts of 5.5 
and 4.4 kb that were coordinately expressed in  culture cells 
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FIG. 8. Northern hybridizations and PCR analysisof mRNA 
from normal  human lung fibroblasts stimulated with serum 
or PMA. A, confluent  normal  human  lung  fibroblasts were incubated 
for 3  h in serum-free  MEM, and  then  the media were replaced with 
fresh MEM containing either 10%  FCS or 0.1 p~ PMA and incubated 
for various intervals. Total RNA was isolated as described under 
“Materials and Methods,” and 5-pg aliquots were analyzed by North- 
ern hybridizations with the HCO-T9 clone (specific activity, 2.6 X 
10xcpm/pg)  and a  murine glyceraldehyde-3-phosphate dehydrogenase 
cDNA (specific activity, 2.5 X loR cpmlpg).  Lane 1, control;  lane 2, 
FCS,  2 h; lane 3, FCS, 4 h; lane 4, FCS, 6 h; lane 5, PMA, 4 h.  B, four 
pg of total RNA were reverse-transcribed and amplified by PCR for 
20 cycles. Equal  aliquots of each  reaction were electrophoresed on  a 
5% acrylamide gel and processed as described under “Materials  and 
Methods.” An autoradiograph of a 2-h exposure of the gel is shown. 
Lane I ,  control; lane 2, FCS, 2 h; lane 3, FCS, 4 h; lane 4 ,  FCS, 6 h; 
lane 5, PMA, 4 h. 
under the  treatments explored. Whether  the 4.4- and 5.5-kb 
transcripts are from related genes or represent immature 
forms of PGG/HS mRNA remains to be determined. The 
presence of two pools of PGG/HS in human endothelial cells 
(40) and monocytes (41) and  the identification of two anti- 
genically distinct  variants of PGG/HS localized to specific 
cell types in the  rat ovary (42) suggest that  the 5.5- and 4.4- 
kb transcripts may correspond to genes coding for different 
proteins with cyclooxygenase activity. The cloning of a  murine 
PMA-induced 4-kb cDNA corresponding to a  protein with a 
predicted amino acid sequence that is 80% homologous to 
PGG/HS supports this possibility (43). 
The HCO-T9 clone we isolated is a 2.3-kb cDNA containing 
the entire translated coding region of the human PGG/HS, 
as compared with an ovine cDNA (7) and a human genomic 
clone (ll), except that  it lacked a  fragment corresponding to 
the  last 111 bp encoded by exon 9. This observation suggested 
an alternative splicing of PGG/HS transcripts.  PCR ampli- 
fication of reverse-transcribed mRNA and  the presence of a 
consensus 5“splice donor site at  the  area around position 
1185 (33) confirmed this notion. Because the alternative 
splicing occurs in-frame, it is expected that  it will  be trans- 
lated into  an identical protein, except for the lack of residues 
The  intact  and spliced PGG/HS  transcripts were found  in 
mRNA extracted directly from tissues (synovium and carti- 
lage) or from cultured cells (dermal, synovial, and lung fibro- 
blasts), indicating that alternative splicing of PGG/HS 
mRNA is a  naturally occurring phenomenon. Treatment of 
normal  human lung fibroblasts with the inducers of PG pro- 
duction,  TGF-PI, TNF-a,  IL-lP, serum, and PMA, increased 
the steady-state levels of PGG/HS mRNA. PCR amplification 
of RNA from stimulated cells showed that each of these 
396-432. 
conditions increased the expression of the  intact  and spliced 
transcripts. However, all conditions caused a preferential 
stimulation of the  intact  transcripts (Table  I). 
PGG/HS is a membrane-bound glycosylated protein with 
bisdioxygenase and hydroperoxide activities that requires a 
heme group for each 70-kDa monomer for the expression of 
both catalytic activities. The bisdioxygenase and hydroper- 
oxide activities reside on  different domains of the protein (44, 
45). It  has been proposed that  the region responsible for the 
bisdioxygenase activity is located in the  stretch encompassing 
residues 476-546. This region is highly conserved among 
different species and contains the active site SerS3’ (10). It 
has also been shown that  the bisdioxygenase activity of the 
enzyme requires a  tyrosine residue that has been identified 
by site-directed mutagenesis as Tyr3’r’ (46). The hydroperox- 
ide active site appears to reside around His2”-Arg2“R residues 
(47). I t  has been postulated that  the His3m and Hiszz6 residues 
are  the axial and distal heme ligand sites, respectively (10). 
Substitution of Hisqo9 by site-directed mutagenesis completely 
abrogated both enzymatic activities of PGG/HS (48). The 
alternative splicing of the  PGG/HS  transcripts from exon 9 
demonstrated here spares  all  these critical regions and resi- 
dues. 
The human  PGG/HS has four potential glycosylation sites 
located at  residues AsnIn3, and Am4@’. These 
are considered to be involved in  maintaining the conformation 
of the  tertiary structure, as well as in  anchoring the enzyme 
to  the cell membrane. Site-directed mutagenesis has shown 
that substitution of the Am4’’ of the ovine enzyme completely 
abrogates its cyclooxygenase activity (48). The corresponding 
residue in  the human enzyme is eliminated by the 
alternative splicing of PGG/HS  transcripts from exon 9. The 
elimination of Am4@’ is the most important alteration of the 
primary structure of the human enzyme that would result 
from the alternative splicing of the PGG/HS transcripts 
described here. The consequences of such alteration on the 
function of the  translated protein are, at  the moment, only 
speculative. However, the findings that the expression of 
nonspliced transcripts is preferentially stimulated by cyto- 
kines and growth factors known to increase PG production 
suggests that  the alternative splicing of transcripts encoded 
by exon 9 may be a mechanism to limit the conversion of 
arachidonic acid to PG and thromboxanes at  an early step of 
the biosynthetic pathway. Critical functional studies of the 
protein coded  by the spliced transcripts  are in  progress. 
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Addendum-While this manuscript was being prepared, the se- 
quence of a human platelet/erythroleukemia cell PGG/HS cDNA 
was published (49). 
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